The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy

Table 2

The clinicopathological characteristics of NSCLC patients according to SII status.

Parameters	SII (), (%)		value
	≤480 ()	>480 ()
Sex			0.944
Male	26 (44.8)	30 (45.5)
Female	32 (55.2)	36 (54.5)
Age (years)			0.613
<60	29 (50.0)	30 (45.5)
≥60	29 (50.0)	36 (54.5)
Smoking history			<0.001
Never smoker	35 (60.3)	19 (28.8)
Smoker	23 (39.7)	47 (71.2)
KPS			0.644
90-100	27 (46.6)	28 (42.4)
70-80	31 (53.4)	38 (57.6)
Histology type			0.398
SCC	18 (41.4)	16 (24.2)
AD	40 (58.6)	50 (75.8)
Differentiation			0.660
Well/moderate	26 (44.8)	27 (40.9)
Poor	32 (55.2)	39 (59.1)
Primary site of tumor			0.963
Right	31 (53.4)	35 (53.0)
Left	27 (46.6)	31 (47.0)
Neurologic symptoms			0.290
No	31 (53.4)	29 (43.9)
Yes	27 (46.6)	37 (56.1)
Primary T stage			0.454
T1-T2	34 (58.6)	43 (65.2)
T3-T4	24 (41.4)	23 (34.8)
Primary N stage			0.065
N0-N1	36 (62.1)	51 (77.3)
N2-N3	22 (37.9)	15 (22.7)
Primary AJCC stage			0.002
I	40 (69.0)	27 (40.9)
II-III	18 (31.0)	39 (59.1)
No. of BM			0.091
1	30 (51.7)	44 (66.7)
2-3	28 (48.3)	22 (33.3)

Abbreviations: KPS: Karnofsky performance status; SCC: squamous cell carcinoma; AD: adenocarcinoma; BM: brain metastasis; SII: systemic immune-inflammation index.